Literature DB >> 3326815

The contribution of immunohistochemical staining in tumour diagnosis.

A S Leong1, J Wright.   

Abstract

With the increasing use of immunohistochemical stains in the diagnostic laboratory, it becomes relevant to review the contributions of this new technology in the area of tumour diagnosis. During 1986, our laboratory received 21,479 biopsy specimens of which 2013 were tumours. Nine hundred and fifty-eight tumours (47.5%) were subjected to immunohistochemical analysis. The biopsy and immunohistochemistry reports of 200 consecutive tumours, including 41 consultation cases, were retrospectively reviewed and assigned to one of the five categories. Immunohistochemical stains confirmed the preferred H & E diagnosis in 106 cases (53%); made the definitive diagnosis from a list of differential diagnosis in 29 cases (14.5%); provided contributory information in 36 cases (18%); were non-contributory in 27 cases (13.5%); and rendered an unsuspected diagnosis in two cases (1%). Immunohistochemical stains were particularly useful in distinguishing between malignant lymphoma and anaplastic carcinoma and in the identification of amelanotic melanoma. The application of a panel of antibodies chosen in accordance with the differential diagnoses considered was very useful in the typing of anaplastic round cell and spindle cell tumours. In 27 cases (13.5%), immunohistochemical stains were non-contributory. About half of these were referred cases and the failure to demonstrate the relevant antigens in normal tissues which served as in-built controls suggested that part of the problem may be due to differences in methods of fixation which led to sub-optimal preservation of tissue antigens. We conclude that immunohistochemical stains provide important and sometimes essential information for definitive typing of anaplastic tumours. Often the information derived was of therapeutic and prognostic relevance. We argue that this is a cost-effective test although we would caution that in all circumstances the interpretation of immunostaining must be made in the context of the histological as well as the clinical and laboratory data.

Entities:  

Mesh:

Year:  1987        PMID: 3326815     DOI: 10.1111/j.1365-2559.1987.tb01874.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  8 in total

1.  Histogenesis of human renal cell carcinoma by using electron microscopy and immunohistochemical techniques.

Authors:  Attalla F El-Kott; Mohamed F Ismaeil; Moustafa M Abd El-Moneim; Mahmoud A El-Baz
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

2.  Determination of lung as the primary site of cerebral metastatic adenocarcinomas using monoclonal antibody to thyroid transcription factor-1.

Authors:  R J Bohinski; P A Bejarano; G Balko; R E Warnick; J A Whitsett
Journal:  J Neurooncol       Date:  1998-12       Impact factor: 4.130

3.  Immunohistochemistry as an important tool in biomarkers detection and clinical practice.

Authors:  Leandro Luongo de Matos; Damila Cristina Trufelli; Maria Graciela Luongo de Matos; Maria Aparecida da Silva Pinhal
Journal:  Biomark Insights       Date:  2010-02-09

4.  Anti-diabetic effect of a novel oligosaccharide isolated from Rosa canina via modulation of DNA methylation in Streptozotocin-diabetic rats.

Authors:  Gholamreza Bahrami; Soraya Sajadimajd; Bahareh Mohammadi; Razieh Hatami; Shahram Miraghaee; Samira Keshavarzi; Mozafar Khazaei; Seyed Hamid Madani
Journal:  Daru       Date:  2020-08-03       Impact factor: 3.117

5.  Relative usefulness of electron microscopy and immunocytochemistry in tumour diagnosis: 10 years of retrospective analysis.

Authors:  A U Dar; P M Hird; B E Wagner; J C Underwood
Journal:  J Clin Pathol       Date:  1992-08       Impact factor: 3.411

6.  Enabling automated and reproducible spatially resolved transcriptomics at scale.

Authors:  Linnea Stenbeck; Fanny Taborsak-Lines; Stefania Giacomello
Journal:  Heliyon       Date:  2022-06-11

7.  Applications of immunohistochemistry.

Authors:  Jeyapradha Duraiyan; Rajeshwar Govindarajan; Karunakaran Kaliyappan; Murugesan Palanisamy
Journal:  J Pharm Bioallied Sci       Date:  2012-08

Review 8.  Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy?

Authors:  Young Kwang Chae; Ayush Arya; Lauren Chiec; Hiral Shah; Ari Rosenberg; Sandip Patel; Kirtee Raparia; Jaehyuk Choi; Derek A Wainwright; Victoria Villaflor; Massimo Cristofanilli; Francis Giles
Journal:  Oncotarget       Date:  2017-08-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.